Thermo Fisher expands proteomics offering

Published: 15-Nov-2021

The company will showcase its latest offerings and collaborations at the Human Proteome Organization Reconnect event

Thermo Fisher Scientific has announced additional proteomics products and co-marketing agreements designed to advance the throughput, comprehensiveness and quality of proteomics workflows for applications such as single-cell studies and translational research.

The company will showcase these relationships, as well as the additions to its offering of mass spectrometry (MS) and chromatography instruments, during the Human Proteome Organization (HUPO) Reconnect event, being held virtually November 15-19.

"Proteomics research has the potential to expand our scientific understanding and uncover new biomarkers to meet unmet medical needs," said Andreas Huhmer, Senior Director, Life Sciences Research Omics Marketing, Thermo Fisher Scientific. "While there has been significant progress in our ability to perform advanced analyses such as single-cell and translational proteomics, there are still improvements needed in the efficiency and reproducibility of workflows. The agreements we’re announcing today, will enable us to continue to deliver innovative proteomics solutions to customers with a goal to make these workflows accessible to everyone."

Thermo Fisher is extending its co-marketing agreement with Biognosys, a developer of proteomics solutions that provides instruments, kits and software for laboratories performing plasma analysis. The company’s PQ500 reference peptide kit is reportedly able to quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow, enabled using the Thermo Scientific Orbitrap Exploris 480 mass spectrometer.

Thermo Fisher has also extended its chromatography portfolio through the acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns. The portfolio of columns is designed to enhance LC performance in biomarker, proteomics and drug research and development applications.

A co-marketing agreement between Thermo Fisher and Cellenion, developer of single-cell sample preparation technologies, is aimed to deliver a sample to results workflow for scientists performing single-cell proteomics analysis. Cellenion’s sample preparation solution, cellenONE, combines single-cell isolation and nanolitre dispensing to perform each step of the sample preparation using a single device, the company says.

You may also like